Analysis
What the official said
“The U.S. Food and Drug Administration today authorized the Aletta, the first standalone robotic device that can draw blood from a patient’s arm without hands-on operator intervention.”
Claimant: U.S. Food and Drug Administration Agency (press release quoting Michelle Tarver, M.D., Ph.D.)
Agency or office: FDA
Context
FDA press release (De Novo authorization) announcing marketing authorization of Vitestro's Aletta device for autonomous blood draws in adults in outpatient settings, with supervisor oversight.
Evidence
The claim is a direct statement from the FDA press release announcing De Novo marketing authorization for the Aletta. As the primary U.S. regulator for medical devices, the FDA's authorization is strong evidence that the device has met the agency's requirements for safety and effectiveness for the specified use. The characterization of Aletta as "the first" standalone robotic blood‑draw device is based on the agency's assessment; confirming the absolute novelty of the device would require a comprehensive review of prior device clearances and international products, but the FDA's De Novo authorization is authoritative for U.S. market status.